Elevated expression of mammalian polo-like kinase (Plk)1 occurs in many different types of
cancers, and Plk1 has been proposed as a novel diagnostic marker for several tumors. We …

Emerging evidences demonstrate that circular RNAs (circRNAs) are abnormally expressed
in tumors and could serve as prognostic markers for cancers. However, the expression …

Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the
treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy …

Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved
for the management of castration-resistant prostate cancer (CRPC). Although patients can …

CLIP‐170 is implicated in the formation of kinetochore–microtubule attachments through direct
interaction with the dynein/dynactin complex. However, whether this important function of …

Altered lipid metabolism is increasingly recognized as a signature of cancer cells. Enabled
by label-free Raman spectromicroscopy, we performed quantitative analysis of lipogenesis at …

Polo-like kinase 1 (Plk1) is a crucial regulator of cell cycle progression; but the mechanism
of regulation of Plk1 activity is not well understood. We present evidence that Plk1 activity is …

We previously reported the phenotype of depletion of polo-like kinase 1 (Plk1) using RNA
interference (RNAi) and showed that p53 is stabilized in Plk1-depleted cancer cells. In this …

Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range of tumors,
prompting research and development of Plk1 inhibitors as a means of cancer treatment. …

… The Plk1 knock-in mouse (Plk1 LSL ) was designed by the Xiaoqi Liu lab at Purdue University,
and constructed by Taconic, Germany. Plk1 LSL mice and were subsequently obtained …